Cynata are in a good position to make gains in coming months. Tomorrow may prove me wrong, but I dont see downside for cyp in the msb fda decision.
If msb is approved it validates stem cell tech with cyp having batch to batch consistency as an extra string to its bow in other conditions. Either no spend on gvhd and full steam ahead on other options or slug it out with msb for adults.
If msb gets knocked back cynata has the consistency argument as the way forward in gvhd.
… in any case, msb win sees cynata with a wide open road
i would have preferred to see killian put some distance in style and substance between himself and past management (taking ops at the recent raise .30 price point would have helped) … but hopefully the new blood helps in driving growth and selling the story as all eyes are on the space.
CYP Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)